36 min listen
The deep dive on Isomer's 100M€ Secondaries Fund with Joe Schorge and Omalade Adebisi | E302
FromEUVC
The deep dive on Isomer's 100M€ Secondaries Fund with Joe Schorge and Omalade Adebisi | E302
FromEUVC
ratings:
Length:
60 minutes
Released:
Apr 26, 2024
Format:
Podcast episode
Description
The landscape of venture capital is evolving, and Isomer Capital is at the forefront with its new fund designed to meet the dynamic needs of the European venture capital market.We sat down with Joe Schorge and Omolade Adebisi from Isomer to talk through the market, the strategy and the future. Well-worth a watch as we open up the deck that raised the fund and tap the brains that incept and run it. But let’s get the headline numbers in place:100 M€ Fund dedicated to secondaries exclusively.65-75% of dedicated to acquiring Limited Partner (LP) interests in existing VC funds.An additional 15-25% is earmarked for direct secondaries in companies, providing crucial liquidity to stakeholders.The remaining funds, up to 15%, are reserved for discretionary investments, which may include buying stakes or carry from general partners.This strategic distribution of funds is a response to the current market conditions where many European VCs have yet to realize significant returns from their investments. These circumstances often necessitate liquidity solutions for personal reasons—such as purchasing homes or funding private education—or professional requirements like meeting General Partner (GP) commitments for raising new funds.Typical ticket sizes range from €1 million to €10 million injecting much-needed flexibility and liquidity across Europe's venture capital ecosystem and broadening Isomer’s impact beyond the traditional fund of funds model to include any Europe-based fund or startup ?Hope you’ll enjoy the read and watch on eu.vc and the listen here on your pod player ?
Released:
Apr 26, 2024
Format:
Podcast episode
Titles in the series (100)
#1 Marc Lohrmann, Vesalius Biocapital: Episode 1 features Marc Lohrmann, Managing Partner of Vesalius Biocapital III, a 120 €M venture capital fund investing in late-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, across all of Europe. Prior to... by EUVC